SEARCH

SEARCH BY CITATION

REFERENCES

  • Adjuik M, Babiker A, Garner P, Olliaro P, Taylor W, White N. 2004. Artesunate combinations for treatment of malaria: meta-analysis. Lancet 363:917.
  • Bate R, Coticelli P, Tren R, Attaran A. 2008. Antimalarial drug quality in the most severely malarious parts of Africa—a six country study. PLoS ONE 3:e2132.
  • Bosman A, Mendis KN. 2007. A major transition in malaria treatment: the adoption and deployment of artemisinin-based combination therapies. Am J Trop Med Hyg 77(Suppl 6):193197.
  • Burgess RW, Bray RS. 1961. The effect of a single dose of primaquine on the gametocytes, gametogony and sporogony of Laverania falciparum. Bull WHO 24:451456.
  • Dellicour S, Hall S, Chandramohan D, Greenwood B. 2007. The safety of artemisinins during pregnancy: a pressing question. Malar J 6:15.
  • Dondorp A, Nosten F, Stepniewska K, Day N, White N. 2005. South East Asian Quinine Artesunate Malaria Trial (SEAQUAMAT) group. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 366:717725.
  • Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Warunee Hanpithakpong H, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NPJ, Lindegardh N, Socheat D, White NJ. 2009. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 361:455467.
  • Filler SJ, Kazembe P, Thigpen M, Macheso A, Parise ME, Newman RD, Steketee RW, Hamel1 M. 2006. Randomized trial of 2-dose versus monthly sulfadoxine-pyrimethamine intermittent preventive treatment for malaria in HIV-positive and HIV-negative pregnant women in Malawi. J Infect Dis 194:286293.
  • Gomes MF, Faiz MA, Gyapong JO, Warsame M, Agbenyega T, Babiker A, Baiden F, Yunus EB, Binka F, Clerk C, Folb P, Hassan R, Hossain MA, Kimbute O, Kitua A, Krishna S, Makasi C, Mensah N, Mrango Z, Olliaro P, Peto R, Peto TJ, Rahman MR, Ribeiro I, Samad R, White NJ; Study 13 Research Group. 2009. Pre-referral rectal artesunate to prevent death and disability in severe malaria: a placebo-controlled trial. Lancet 373:566577.
  • Goodman C, Brieger B, Unwin A, Mills A, Meek S, Greer G. 2007. Medicine sellers and malaria treatment in Sub-Saharan Africa: what do they do and how can their practice be improved? Am J Trop Med Hyg 77:203218.
  • Greenwood B. 2006. Intermittent preventive treatment—a new approach to the prevention of malaria in children in areas with seasonal malaria transmission. Trop Med Int Health 11:983991.
  • Hay SI, Guerra1 CA, Peter W. Gething PW, Patil AP, Tatem AJ, Noor AM, Kabaria1 CW, Manh BH, Elyazar IRF, Brooker S, Smith DL, Moyeed RA, Snow RW. 2009. A world malaria map: Plasmodium falciparum endemicity in 2007. PLoS Med 6.
  • Mendis K, Sina BJ, Marchesini P, Carter R. 2001. The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg 64:97106.
  • Mendis K, Rietveld A, Warsame M, Bosman A, Greenwood B, Wernsdorfer W. 2009. From malaria control to eradication: the WHO perspective. Trop Med Int Health 14:802809.
  • MMV. 2008. Ensuring Success and Targeting Eradication: MMV Business Plan 2008–2012. http://www.mmv.org/IMG/pdf/FINALMMV_Business_Plan_2008-2012.pdf
  • Newton PN, Fernández FM, Plançon A, Mildenhall DC, Green MD, Ziyong L, Christophel EM, Phanouvong S, Howells S, McIntosh E, Laurin P, Blum N, Hampton CY, Faure K, Nyadong L, Soong CW, Santoso B, Zhiguang W, Newton J, Palmer K. 2008. A collaborative epidemiological investigation into the criminal fake artesunate trade in South East Asia. PLoS Med 5:e32.
  • Nosten F, Hien TT, White NJ. 1998. Use of artemisinin derivatives for the control of malaria. Med Trop 58(Suppl 3):4549.
  • Omari A, Gamble C, Garner P. 2004. Artemether-lumefantrine for uncomplicated malaria: a systematic review. Trop Med Int Health 9:192199.
  • Price RN, Nosten F, Luxemburger C, Ter Kuile FO, Paiphun L, Chongsuphajaisiddhi T, White NJ. 1996. Effects of Artemisinin derivatives on malaria transmissibility. Lancet 347:16541658.
  • Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, Anstey NM. 2007. Vivax malaria: neglected and not benign. Am J Trop Med Hyg 77(Suppl 6):7987.
  • Pukrittayakamee S, Chotivanich K, Chantra A, Clemens R, Looareesuwan S, White NJ. 2004. Activities of artesunate and primaquine against asexual- and sexual-stage parasites in falciparum malaria. Antimicrob Agents Chemother 48:13291334.
  • RBM Partnership. 2008. The global malaria action plan. Roll Back Malaria, 2008. http://www.rbm.who.int/gmap/gmap.pdf.
  • Singh B, Lee KS, Matusop A, Radhakrishnan A, Shamsul SSG, Cox-Singh J, Thomas A, Conway DJ. 2004. A large focus of naturally acquired Plasmodium knowlesi infections in human beings. Lancet 363:10171024.
  • Steketee RW, Nahlen BL, Parise ME, Menendez C. 2001. The burden of malaria in pregnancy in malaria-endemic areas. Am J Trop Med Hyg 64:2835.
  • Sutherland CJ, Ord R, Dunyo S, Jawara M, Drakeley CJ, Alexander N, Coleman R, Pinder M, Walraven G, Targett GA. 2005. Reduction of malaria transmission to Anopheles mosquitoes with a six-dose Regimen of Co-Artemether. PLoS Med 2:e92.
  • Talisuna AO, Bloland P, D'Alessandro U. 2004. History, dynamics, and public health importance of malaria parasite resistance. Clin Microbiol Rev 17:235254.
  • Trape JF, Pison G, Preziosi MP, Enel C, Desgrées du Louû A, Delaunay V, Samb B, Lagarde E, Molez JF, Simondon F. 1998. Impact of chloroquine resistance on malaria mortality. CR Acad Sci Paris Life Sci 321:689697.
  • White NJ. 1999. Antimalarial drug resistance and combination chemotherapy. Philos Trans R Soc Lond B 354:739749.
  • White NJ. 2008. The role of anti-malarial drugs in eliminating malaria. Malar J 7(Suppl 1):S8.
  • WHO. 2001. Antimalarial drug combination therapy. Report of a WHO Technical Consultation, 4–5 April 2001. Geneva: World Health Organization. WHO/CDS/RBM/2001.35.
  • WHO. 2004. A strategic framework for malaria prevention and control during pregnancy in the Africa Region. Document AFR/MAL/04/01.
  • WHO. 2005a. The Roll Back Malaria strategy for improving access to treatment through home management for malaria. Geneva: World Health Organization.
  • WHO. 2005b. Susceptibility of Plasmodium falciparum to antimalarial drugs. Report on global monitoring, 1996–2004. Geneva: World Health Organization. WHO/HTM/MAL/2005.1103.
  • WHO. 2007. Malaria elimination. A field manual for low and moderate endemic countries. Geneva: World Health Organization. http://apps.who.int/malaria/docs/elimination/MalariaElimination_BD.pdf.
  • WHO. 2008. World Malaria Report. World Health Organization, Geneva. http://apps.who.int/malaria/wmr2008/malaria2008.pdf.
  • WHO. 2009a. WHO guidelines for the treatment of malaria. 2nd edition. Geneva: World Health Organization. In press.
  • WHO. 2009b. International Travel and Health: Chapter 7 (malaria). Geneva, Switzerland: World Health Organization. http://www.who.int/topics/malaria/en/index.html
  • WHO. 2009c. Report of the Technical Consultation on Intermittent Preventive Treatment in Infants (IPTi), 23–24 April 2009. Geneva, Switzerland: WHO. http://malaria.who.int/docs/IPTi/TEGConsultIPTiApr2009Report.pdf
  • Zucker JR, Ruebush TK, Obonyo C, Otieno J, Campbell CC. 2003. The mortality consequences of the continued use of chloroquine in Africa: experience in Siaya, western Kenya. Am J Trop Med Hyg 68:386390.